Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.58 |
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804977 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL13127508 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL3648306 | 0.93 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL3648305 | 0.93 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL13127510 | 0.87 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL13127509 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL2812638 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL2812640 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL2809964 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10HTT | |
| SCHEMBL2809962 | 0.83 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | claimed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-8592446-B2 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2013-11-26 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, PARK7, ATXN10 | KDM4E 1412/4885ALDH1A1 319/4885HPGD 483/4885 |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, ATXN10, PSEN1 | KDM4E 1922/4885ALDH1A1 1502/4885HPGD 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.